or Try an Advanced Search...

    Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

    Grade Last Price % Change Price Change
    C 45.51 -2.82% -1.32
    BHVN closed up 1.14 percent on Wednesday, November 20, 2024, on 73 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical BHVN trend table...
    Date Alert Name Type % Chg
    Older End-of-Day Signals for BHVN ...

       Recent Intraday Alerts

    Alert Time
    No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BHVN Chart by TradingView
    Basic chart:

    Profile

    Biohaven Pharmaceutical Holding Company Ltd. Description

    Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Neuroscience Organic Compounds Chemical Compounds Neurodegenerative Diseases Glutamate Neurotransmitters Chemical Entity N Methyl D Aspartic Acid Riluzole

    Is BHVN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Biohaven Non-GAAP EPS of -$1.74 misses by $0.24
    Nov 12 Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
    Oct 21 Top small-cap stock picks from Morgan Stanley following the group's upgrade to neutral
    Oct 11 Biohaven: A Complicated Tale
    Oct 7 Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy
    Oct 3 Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock
    Oct 1 Biohaven prices $250M share offering
    Oct 1 Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
    Oct 1 Acuity Brands, Nike And 3 Stocks To Watch Heading Into Tuesday
    Sep 30 Biohaven proposed public offering of common shares
    See more BHVN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 62.21
    52 Week Low 26.8
    Average Volume 1,079,730
    200-Day Moving Average 43.76
    50-Day Moving Average 48.77
    20-Day Moving Average 50.21
    10-Day Moving Average 49.00
    Average True Range 2.58
    RSI (14) 42.20
    ADX 26.08
    +DI 18.06
    -DI 26.58
    Chandelier Exit (Long, 3 ATRs) 47.23
    Chandelier Exit (Short, 3 ATRs) 50.93
    Upper Bollinger Bands 55.51
    Lower Bollinger Band 44.91
    Percent B (%b) 0.18
    BandWidth 21.11
    MACD Line -0.81
    MACD Signal Line 0.05
    MACD Histogram -0.8607
    Fundamentals Value
    Market Cap 3.76 Billion
    Num Shares 80.2 Million
    EPS -7.23
    Price-to-Earnings (P/E) Ratio -6.48
    Price-to-Sales 0.00
    Price-to-Book 13.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 50.21
    Resistance 3 (R3) 49.96 48.58 49.65
    Resistance 2 (R2) 48.58 47.72 48.71 49.46
    Resistance 1 (R1) 47.70 47.19 48.14 47.96 49.27
    Pivot Point 46.33 46.33 46.54 46.45 46.33
    Support 1 (S1) 45.45 45.46 45.89 45.70 44.39
    Support 2 (S2) 44.07 44.93 44.20 44.20
    Support 3 (S3) 43.20 44.07 44.01
    Support 4 (S4) 43.45